Fresenius Medical Care AG & Co. KGaA Sponsored ADR Stock

$22.56

1.81% yesterday

NYSE, Nov 25, 10:10 pm CET

ISIN

US3580291066

Symbol

FMS

Reports

Quarter | Annual

Index

CDAX, NYSE Composite

Sector

Health

Industry

Health service provider

Overview Dividends Analysts Charts News Strategies

Fresenius Medical Care AG & Co. KGaA Sponsored ADR Stock price

$22.56

-14.43 39.01% 5Y

NYSE, Closing price Mon, Nov 25 2024

+0.40 1.81%

ISIN

US3580291066

Symbol

FMS

Reports

Quarter | Annual

Index

CDAX, NYSE Composite

Sector

Health

Industry

Health service provider

Key metrics

Market capitalization	$13.24b
Enterprise Value	$25.52b
P/E (TTM) P/E ratio	18.53
EV/FCF (TTM) EV/FCF	15.02
EV/Sales (TTM) EV/Sales	1.22
P/S ratio (TTM) P/S ratio	0.63
P/B ratio (TTM) P/B ratio	0.87
Dividend yield	2.85%
Last dividend (FY24)	$0.64
Revenue growth (TTM) Revenue growth	0.42%
Revenue (TTM) Revenue	$20.85b
EBIT (operating result TTM) EBIT	$1.77b
Free Cash Flow (TTM) Free Cash Flow	$1.70b
Cash position	$1.53b
EPS (TTM) EPS	$1.22
P/E forward	17.92
P/S forward	0.64
EV/Sales forward	1.23
Short interest	0.20%

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Get Started for Free Today

Fresenius Medical Care AG & Co. KGaA Sponsored ADR Stock Analysis

Unlock Scores for Free

??

20 Analysts have issued a Fresenius Medical Care AG & Co. KGaA Sponsored ADR forecast:

6x Buy

30%

8x Hold

40%

6x Sell

30%

More details on Analyst Estimates Including Price Targets

20 Analysts have issued a Fresenius Medical Care AG & Co. KGaA Sponsored ADR forecast:

Buy

30%

Hold

40%

Sell

30%

Analyst Estimates with Stock Price Targets

Financial data from Fresenius Medical Care AG & Co. KGaA Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	20,852 20,852	2% 2% 100%
- Direct Costs	15,612 15,612	2% 2% 75%
Gross Profit	5,240 5,240	1% 1% 25%
- Selling and Administrative Expenses	1,579 1,579	6% 6% 8%
- Research and Development Expense	216 216	13% 13% 1%
EBITDA	3,445 3,445	3% 3% 17%
- Depreciation and Amortization	1,676 1,676	13% 13% 8%
EBIT (Operating Income) EBIT	1,770 1,770	23% 23% 8%
Net Profit	715 715	15% 15% 3%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Fresenius Medical Care AG & Co. KGaA Sponsored ADR Stock News

Neutral

Seeking Alpha

●

21 days ago

Fresenius Medical Care AG (FMS) Q3 2024 Earnings Call Transcript

Fresenius Medical Care AG (NYSE:FMS ) Q3 2024 Earnings Conference Call November 5, 2024 8:00 AM ET Company Participants Dominik Heger - Head, Investor Relations Helen Giza - Chief Executive Officer and Chair Martin Fischer - Chief Financial Officer Conference Call Participants Richard Felton - Goldman Sachs Victoria Lambert - Berenberg Robert Davies - Morgan Stanley Hugo Solvet - BNP Paribas Ol...

Neutral

PRNewsWire

●

21 days ago

Fresenius Medical Care reports strong operating income margin growth in the third quarter of 2024

Organic revenue growth of +2% supported by Care Enablement and Care Delivery Underlying U.S. dialysis treatment volume growth turns positive Exceeding full year FME25 savings target, with additional EUR 64 million contribution in Q3 Both segments further increased operating income1 and operating income margin1 Net financial leverage ratio further improved to 2.8x FY 2024 operating income1 growt...

Neutral

PRNewsWire

●

about one month ago

Fresenius Medical Care Showcases Research and Innovations in Kidney Care at American Society of Nephrology (ASN) Kidney Week 2024

A dedicated session will highlight new advancements in hemodiafiltration therapy showcasing its potential to improve patient outcomes through enhanced toxin removal in dialysis treatments. Company-wide researchers and clinical experts share insights from large global databases, revealing crucial trends in kidney failure etiology, cardiovascular risks, and treatment modalities across different r...

More Fresenius Medical Care AG & Co. KGaA Sponsored ADR News

Company Profile

Fresenius Medical Care AG & Co. KGaA engages in the provision of products and services for patients with chronic kidney failure. It also develop and manufacture a variety of health care products, which includes dialysis and non-dialysis products. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.

Head office	Germany
CEO	Helen Giza
Employees	119,845
Founded	1996
Website	www.freseniusmedicalcare.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now